Aquestive Therapeutics

Yahoo Finance • 3 days ago

Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID

(RTTNews) - Several small-cap names posted sharp gains in Thursday's after-hours session, driven by fresh corporate updates, clinical developments, and strategic pivots. Below are five stocks that stood out for their notable post-close mov... Full story

Yahoo Finance • 25 days ago

Aquestive jumps as FDA says no AdCom for allergy therapy Anaphylm

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Aquestive Therapeutics (NASDAQ:AQST [https://seekingalpha.com/symbol/AQST]) added ~15% in the premarket on Thursday after announcing t... Full story

Yahoo Finance • 25 days ago

Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquest... Full story

Yahoo Finance • 2 months ago

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ... Full story

Yahoo Finance • 2 months ago

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company’s balance sheet in advance of potential commercialization of Anaphylm... Full story

Yahoo Finance • 2 months ago

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

FDA accepts NDA submission for Anaphylm™; PDUFA date set for January 31, 2026Planning continues for a Q1 2026 U.S. launch of Anaphylm, if approved by the FDACompany accelerates Anaphylm global expansion strategy to Canada and the EUCompany... Full story

Yahoo Finance • 2 months ago

Barrick Gold, Roivant Sciences, Owens & Minor to report earnings Monday

Earnings season continues, with several notable companies set to release their financial results for the upcoming trading day. Leading the pack are mining giant Barrick Gold, biopharmaceutical company Roivant Sciences (NASDAQ:ROIV), and he... Full story

Yahoo Finance • 2 months ago

Aquestive schedules regulatory meetings for epinephrine film in Canada, EU

WARREN, N.J. - Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company with a market capitalization of $400 million and showing strong momentum with a 9.5% return last week, announced today that Health Canada has granted the c... Full story

Yahoo Finance • 2 months ago

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, In... Full story

Yahoo Finance • 3 months ago

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative... Full story

Yahoo Finance • 3 months ago

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ... Full story

Yahoo Finance • 3 months ago

Aquestive gains as allergy therapy undergoes FDA review

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images * Aquestive Therapeutics (NASDAQ:AQST [https://seekingalpha.com/symbol/AQST]) added ~5% in the premarket on Monday after the biophar... Full story

Yahoo Finance • 4 months ago

Aquestive Therapeutics, Inc. (AQST): Analysts See 245% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Aquestive Therapeutics (NASDAQ:AQST) was one of the stocks that was covered in that article. Wall Street analysts believe AQST has a 245% upside potential... Full story

Yahoo Finance • 7 months ago

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDAAnaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDAInitial Anaphylm pediatric clinical trial results in subjects 7-17... Full story

Yahoo Finance • 8 months ago

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water submersionNew findings demonstrate dosing of Anaphylm results in consistent epinephrine... Full story

Yahoo Finance • 2 years ago

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting

WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ... Full story

Yahoo Finance • 2 years ago

Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Reiterates commencement of pivotal pharmacokinetic (PK) study for Anaphylm™ (epinephrine) Sublingual Film expected in fourth quarter 2023 with topline data targeted for first quarter 2024Completes debt refinancing resulting in approximatel... Full story

Yahoo Finance • 2 years ago

Aquestive Therapeutics Completes $45 Million Debt Refinancing

WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technolog... Full story

Yahoo Finance • 2 years ago

Aquestive Therapeutics Provides Business Update

Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual FilmReaffirms fourth quarter 2023 Anaphylm pivotal Phase 3 study start and first quarter 2024 topline data readoutOutlines expected remain... Full story

Yahoo Finance • 2 years ago

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to i... Full story